Axon Enterprise
AXON
$345.94
-1.53%
Axon Enterprise, Inc. is a technology company operating in the public safety and defense sector, building an integrated ecosystem of hardware devices and cloud software solutions. The company is a market leader and disruptor, known for its TASER energy weapons, body-worn cameras, and its cloud-hosted digital evidence management platform, which collectively form a comprehensive public safety operating system. The current investor narrative is dominated by a sharp stock price correction and debates over valuation, with recent news highlighting a significant rebound after a steep sell-off, strong analyst support framing the drop as an overreaction, and ongoing discussions about the company's long-term growth potential driven by AI innovation and geopolitical tailwinds in the defense sector.…
AXON
Axon Enterprise
$345.94
Related headlines
Investment Opinion: Should I buy AXON Today?
Rating & Thesis: Hold. Axon presents a high-risk, high-potential opportunity where severe technical damage and valuation risk currently outweigh strong fundamental growth and bullish analyst sentiment, suggesting investors should wait for evidence of a profitability turnaround before committing new capital.
Supporting Evidence: The stock's extreme 365.5x trailing P/E reflects peak expectations on depressed earnings, while its more reasonable 32.7x forward P/E still commands a sector premium that demands flawless execution. Positively, revenue growth remains robust at 38.5% YoY, gross margins are healthy at 57.9%, and TTM free cash flow is positive at $75.1M. However, these strengths are counterbalanced by net margin volatility (0.38% in Q4) and a stock price down 45% over three months, trading just 2% above its 52-week low.
Risks & Conditions: The two biggest risks are 1) further multiple compression if quarterly earnings fail to show consistent profit expansion, and 2) a technical breakdown below $339 triggering another leg down. This Hold rating would upgrade to Buy if the stock demonstrates two consecutive quarters of expanding net margins above 5% while holding the $339 support, or if the forward P/E compresses below 25x on sustained growth. It would downgrade to Sell if revenue growth decelerates below 20% YoY or if the stock breaks below $330. Based on current data, the stock is overvalued on a trailing basis but fairly-to-richly valued on forward estimates given its growth profile and sector peers.
Sign up to view all
AXON 12-Month Price Forecast
Axon is at a critical inflection point where strong top-line growth conflicts with broken price action and valuation risk. The neutral stance reflects the high probability (50%) base case of a grinding, modest recovery contingent on profitability stabilization. The path to a bullish outcome requires clear evidence of operating leverage, which has been absent. Conversely, the bear case is a tangible risk given the stock's proximity to support and high volatility. The stance would upgrade to bullish on two consecutive quarters of margin expansion and a confirmed technical reversal above $400. It would turn bearish on a breakdown below $330 or a material growth slowdown.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axon Enterprise's 12-month outlook, with a consensus price target around $449.72 and implied upside of +30.0% versus the current price.
Average Target
$449.72
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$277 - $450
Analyst target range
Analyst coverage for Axon is active with 8 firms providing estimates, and the institutional rating data shows a predominantly bullish sentiment, with recent actions including 'Overweight' from Morgan Stanley, Barclays, and Piper Sandler, and a 'Buy' from Needham, alongside a 'Neutral' from UBS. The consensus recommendation leans strongly towards Buy, though the absence of a specific average target price in the data necessitates stating that the implied upside or downside cannot be calculated precisely from the provided inputs. The target price range and signal strength cannot be quantified from the given analyst data, which includes revenue and EPS estimates but not price targets. However, the recent pattern of reiterated bullish ratings following earnings and the stock's decline, as noted in news snippets, suggests analysts view the sell-off as an overreaction. The wide dispersion in historical valuation multiples and the stock's high volatility indicate underlying uncertainty and a lack of strong conviction on a stable fair value, which is typical for a company undergoing a transition in its profitability profile.
Bulls vs Bears: AXON Investment Factors
The investment debate for Axon is sharply divided between robust fundamental growth and catastrophic technical and valuation deterioration. The bull case is anchored in strong 38.5% revenue growth, healthy gross margins, and supportive analyst sentiment viewing the sell-off as overdone. The bear case is powerfully evidenced by extreme profitability volatility, an exorbitant 365.5x trailing P/E, and a stock price in freefall, down 45% in three months and trading near 52-week lows. Currently, the bearish evidence carries more weight due to the severity of the price collapse and the precarious valuation resting on highly inconsistent earnings. The single most important tension is whether the company can translate its impressive top-line growth into stable and expanding profitability quickly enough to justify its premium forward multiple before further multiple compression occurs.
Bullish
- Robust Revenue Growth: Q4 2025 revenue grew 38.5% year-over-year to $796.7 million, demonstrating strong top-line demand for Axon's public safety ecosystem. This growth trajectory supports the narrative of a high-growth technology platform within the defense sector.
- Strong Analyst Support: Analyst sentiment is predominantly bullish, with recent 'Overweight' and 'Buy' ratings from major firms like Morgan Stanley and Needham. This support, following a steep sell-off, frames the price decline as an overreaction and suggests institutional confidence in a recovery.
- Healthy Gross Margin Profile: The company maintains a robust gross margin of 57.9% (Q4 2025), indicating pricing power and a favorable product mix. This provides a solid foundation for future profitability as operating expenses are brought under control.
- Positive Free Cash Flow: Trailing twelve-month free cash flow is positive at $75.1 million, demonstrating the company's ability to fund operations and growth internally. This reduces reliance on external financing despite heavy investment phases.
Bearish
- Extreme Profitability Volatility: Net income swung from $135.2 million in Q4 2024 to just $3.0 million in Q4 2025, with a net margin of 0.38%. This erratic earnings profile, including a net loss in Q3 2025, undermines confidence in the business model's scalability and creates significant valuation uncertainty.
- Exorbitant Trailing Valuation: The trailing P/E ratio of 365.5x is astronomically high, indicating the stock is priced for peak earnings expectations relative to depressed current profits. This leaves the stock highly vulnerable to multiple compression if earnings growth disappoints.
- Severe Technical Breakdown: The stock is down 37.24% over the past year and trades at just 7.6% of its 52-week range, hovering near its 52-week low of $339.225. This deep bear market, with a -60.28% maximum drawdown, signals intense selling pressure and broken investor confidence.
- High Volatility and Beta: With a beta of 1.605, Axon is approximately 60% more volatile than the S&P 500. This high volatility has exacerbated recent losses and makes the stock unsuitable for risk-averse investors, increasing the potential for further sharp declines in a weak market.
AXON Technical Analysis
The stock is in a severe and sustained downtrend, having declined 37.24% over the past year and currently trading at a mere 7.6% of its 52-week range, with a current price of $345.94 positioned just above the 52-week low of $339.225. This positioning near the absolute lows indicates the stock is in a deep bear market, presenting a potential value trap or a falling knife scenario rather than a clear-cut opportunity, as it suggests a complete breakdown of prior support levels and significant investor capitulation. Recent momentum is decisively negative and accelerating, with the stock down 33.16% over the past month and 45.24% over the past three months, a sharp divergence from the broader market's modest gains and indicating intense, company-specific selling pressure. The stock's beta of 1.605 confirms it is approximately 60% more volatile than the S&P 500, which has exacerbated losses during this downturn and necessitates careful risk management for any potential position. Key technical support is firmly established at the recent 52-week low of $339.225, while resistance is far overhead at the 52-week high of $885.92. A breakdown below the $339 support level would signal a continuation of the downtrend and potentially trigger further technical selling, whereas any meaningful recovery would need to contend with multiple resistance levels formed during the steep decline. The stock has experienced a maximum drawdown of -60.28% during the provided period, underscoring the extreme volatility and risk inherent in the current price action, which aligns with its high beta and suggests it is unsuitable for risk-averse investors.
Beta
1.60
1.60x market volatility
Max Drawdown
-60.3%
Largest decline past year
52-Week Range
$339-$886
Price range past year
Annual Return
-37.2%
Cumulative gain past year
| Period | AXON Return | S&P 500 |
|---|---|---|
| 1m | -33.2% | +2.6% |
| 3m | -45.2% | -2.3% |
| 6m | -50.8% | +2.6% |
| 1y | -37.2% | +27.3% |
| ytd | -38.6% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXON Fundamental Analysis
Revenue growth remains robust but shows signs of volatility on a quarterly basis; the most recent Q4 2025 revenue was $796.7 million, representing a strong 38.5% year-over-year growth, though this follows a quarter (Q3 2025) with revenue of $710.6 million and a net loss. The multi-quarter trend indicates top-line expansion is continuing, but profitability has been inconsistent, which is a critical point for the investment thesis as it questions the sustainability of growth without commensurate earnings. Profitability is highly inconsistent, with the company swinging between significant profits and losses; Q4 2025 net income was a modest $3.0 million (net margin of 0.38%), a sharp contrast to the $135.2 million profit in Q4 2024. The gross margin remains healthy at 57.9% for Q4 2025, but operating margins have been negative or minimal in recent quarters, indicating high operating expenses are compressing bottom-line results and challenging the path to consistent profitability. The balance sheet appears liquid with a current ratio of 2.53, and the company maintains a moderate debt level with a debt-to-equity ratio of 0.59. Free cash flow over the trailing twelve months is positive at $75.1 million, and Return on Equity (ROE) is 3.85%, suggesting the company can fund some operations internally but is not generating high returns on shareholder capital, pointing to a phase of heavy investment that has yet to translate into strong financial performance.
Quarterly Revenue
$796724000.0B
2025-12
Revenue YoY Growth
+0.38%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$75081000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXON Overvalued?
Given the company's minimal but positive net income in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is an extremely high 365.5x, while the forward PE is a more reasonable 32.7x; this massive gap implies the market is pricing in a significant recovery and acceleration in earnings growth over the next year, betting heavily on a turnaround from recent profit volatility. Compared to sector averages, Axon's valuation is at a substantial premium; its forward PE of 32.7x is elevated for the Industrials/Aerospace & Defense sector, which typically trades at lower multiples. This premium suggests the market values Axon more as a high-growth technology platform within defense, rather than a traditional industrial contractor, and is willing to pay up for its unique market position and software-driven margins, though this premium is being tested by the recent price collapse. Historically, the stock's current trailing PE of 365.5x is near the extreme high end of its own range, as seen in recent quarterly data where PE ratios have fluctuated wildly from negative values to over 3800x. This indicates the stock is pricing in peak expectations relative to depressed earnings, a precarious position that leaves it vulnerable to multiple compression if earnings growth does not materialize as anticipated.
PE
365.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -6436x~3805x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
236.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axon's primary financial risk is extreme earnings volatility, as evidenced by net income collapsing from $135.2M to $3.0M year-over-year in Q4. This erratic profitability, coupled with an operating margin of -2.2%, indicates high operating expenses are consuming healthy gross profits, challenging the path to consistent bottom-line results. While the balance sheet is liquid with a 2.53 current ratio and moderate 0.59 debt-to-equity, the company's 3.85% ROE suggests heavy investment is not yet generating strong returns for shareholders, raising questions about capital allocation efficiency.
Market & Competitive Risks: The most acute market risk is valuation compression. Trading at a forward P/E of 32.7x, a significant premium to typical industrials/defense peers, Axon is priced as a high-growth tech story. Any disappointment in growth or profitability could trigger severe multiple contraction. Furthermore, the stock's high 1.605 beta means it is highly sensitive to broader market downturns, which have already contributed to its 37% annual decline against the S&P 500's 29.5% gain. Competitive and regulatory risks are also present, as seen in news regarding privacy concerns for surveillance technology which could impact public sector adoption.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, where failing to stabilize profitability leads to analyst downgrades and a full derating of the stock from its growth premium. A breakdown below the key $339.225 support level could trigger accelerated technical selling. In this adverse scenario, a realistic downside could see the stock re-testing levels from its -60% drawdown, implying a potential further decline of 35-50% from the current $345.94 price. Investors could face significant losses, with the stock potentially falling towards the $200-$250 range if sentiment completely sours and growth expectations are reset.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Extreme earnings volatility, with net income collapsing from $135M to $3M year-over-year, challenges the investment thesis. 2) Valuation Risk: The 365.5x trailing P/E leaves the stock vulnerable to severe multiple compression if growth stumbles. 3) Technical/Momentum Risk: The stock is in a deep bear market, down 37% over the past year and trading near 52-week lows, which can become self-reinforcing. 4) Volatility Risk: A beta of 1.605 means AXON will fall more than the market in downturns, as recently demonstrated.
The 12-month forecast is bifurcated with a base case target of $450-$550 (25% to 50% upside from ~$346), a bull case of $650-$750 (85% to 115% upside), and a bear case of $300-$400 (13% downside to 15% upside). The most likely scenario (50% probability) is a base case of modest recovery as the stock consolidates and profitability slowly improves, aligning with a forward P/E around 30x. The key assumption for this base case is that revenue growth remains above 25% while net margins expand to the low single digits. The wide range reflects the high uncertainty stemming from earnings volatility.
AXON's valuation presents a paradox. It is severely overvalued based on trailing earnings, with a P/E of 365.5x due to depressed recent profits. On a forward basis, the 32.7x P/E is rich relative to the Industrials/Aerospace & Defense sector, implying the market is paying a premium for its technology-led growth profile. This premium valuation is not obviously undervalued; it is fairly valued to slightly overvalued, contingent on the company delivering on high growth and margin expansion expectations embedded in the forward multiple. The market is pricing in a significant earnings recovery.
AXON is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The stock offers significant potential upside if it can stabilize profitability, given its 38.5% revenue growth and strong market position. However, it carries substantial downside risk, trading just above its 52-week low after a 45% three-month decline, with an exorbitant 365.5x trailing P/E. It could be a good buy for aggressive investors willing to average in on weakness, provided they are prepared for further volatility and have conviction in the long-term software-driven margin story.
AXON is unsuitable for short-term trading due to its high beta (1.605) and catastrophic recent momentum, which could lead to swift, unpredictable losses. It is best considered a long-term investment (minimum 3-5 year horizon) for investors who believe in the long-term convergence of public safety and technology. This timeframe allows for the company to potentially realize operating leverage, scale its software margins, and for the current negative sentiment to reverse. The lack of a dividend further supports a growth-oriented, long-term holding strategy.